Satoru Torii

Dr. Satoru Torii

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2002 in Nature Cell Biology
Verified
Journal Article
Closed access
HHHiroshi Hanafusa
Hiroshi Hanafusa
STSatoru Torii
Satoru Torii
TYTakayuki Yasunaga
Takayuki Yasunaga
ENEisuke Nishida
Eisuke Nishida

23 June 2006 in Cancer Science
Verified
Journal Article
Closed access
PDF file
STSatoru Torii
Satoru Torii
TYTakuya Yamamoto
Takuya Yamamoto
YTYoshiki Tsuchiya
Yoshiki Tsuchiya
ENEisuke Nishida
Eisuke Nishida

1 July 2004 in Developmental Cell
Verified
Journal Article
Closed access
STSatoru Torii
Satoru Torii
MKMorioh Kusakabe
Morioh Kusakabe
TYTakuya Yamamoto
Takuya Yamamoto
MMMomoko Maekawa
Momoko Maekawa
ENEisuke Nishida
Eisuke Nishida

1 May 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HHHiroshi Hanafusa
Hiroshi Hanafusa
STSatoru Torii
Satoru Torii
TYTakayuki Yasunaga
Takayuki Yasunaga
KMKunihiro Matsumoto
Kunihiro Matsumoto
ENEisuke Nishida
Eisuke Nishida
Src homology 2-containing phosphotyrosine phosphatase (Shp2) functions as a positive effector in receptor tyrosine kinase (RTK) signaling immediately proximal to activated receptors. However, neither its physiological substrate(s) nor its mechanism of action in RTK signaling has been defined. In this study, we demonstrate that Sprouty (Spry) is a possible target of Shp2. Spry acts as a conserved inhibitor of RTK signaling, and tyrosine phosphorylation of Spry is indispensable for its inhibitory activity. Shp2 was able to dephosphorylate fibroblast growth factor receptor-induced phosphotyrosines on Spry both in vivo and in vitro. Shp2-mediated dephosphorylation of Spry resulted in dissociation of Spry from Grb2. Furthermore, Shp2 could reverse the inhibitory effect of Spry on FGF-induced neurite outgrowth and MAP kinase activation. These findings suggest that Shp2 acts as a positive regulator in RTK signaling by dephosphorylating and inactivating Spry.

21 September 2017 in ACS Chemical Biology
Verified
Journal Article
Closed access
HIHidefumi Iwashita
Hidefumi Iwashita
STSatoru Torii
Satoru Torii
NNNoriyoshi Nagahora
Noriyoshi Nagahora
MIMunetaka Ishiyama
Munetaka Ishiyama
KSKosei Shioji
Kosei Shioji
KOKentaro Okuma
Kentaro Okuma

1 November 2004 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
STSatoru Torii
Satoru Torii
KNKei Nakayama
Kei Nakayama
TYTakuya Yamamoto
Takuya Yamamoto
ENEisuke Nishida
Eisuke Nishida
Spatiotemporal control of the Ras/ERK MAP kinase signaling pathway is a key factor for determining the specificity of cellular responses including cell proliferation, cell differentiation and cell survival. The fidelity of this signaling is regulated by docking interactions as well as scaffolding. Subcellular localization of ERK is controlled by cytoplasmic ERK anchoring proteins that have a nuclear export signal (NES), such as MEK. In quiescent cells, ERK and MEK localize to the cytoplasm. In response to stimulation, dissociation of the MEK-ERK complex is induced and activated ERK translocates to the nucleus. Recently, several negative regulators for Ras/ERK signaling have been identified and their detailed molecular mechanisms have been analyzed. Among them, Sprouty and Sef act as a temporal and a spatial regulator, respectively, for Ras/ERK signaling. Thus, multiple factors are involved in control of Ras/ERK signaling.